Optimization of NULOJIX (Belatacept) Usage as a Means of Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation (CTOT-15)

Trial Profile

Optimization of NULOJIX (Belatacept) Usage as a Means of Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation (CTOT-15)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2016

At a glance

  • Drugs Belatacept (Primary) ; Antithymocyte globulin; Methylprednisolone; Mycophenolate mofetil; Mycophenolate sodium; Tacrolimus
  • Indications Kidney-pancreas transplant rejection
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 15 Sep 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 15 Sep 2015 Planned End Date changed from 1 Oct 2016 to 1 Aug 2016, as reported by ClinicalTrials.gov.
    • 22 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top